Royal Bank of Canada Has $1.60 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH

Royal Bank of Canada raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 847.5% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 19,064 shares of the company’s stock after acquiring an additional 17,052 shares during the period. Royal Bank of Canada’s holdings in Dianthus Therapeutics were worth $1,601,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in DNTH. Vestal Point Capital LP increased its position in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vanguard Group Inc. lifted its position in Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after acquiring an additional 406,254 shares in the last quarter. TCG Crossover Management LLC lifted its position in Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after acquiring an additional 175,000 shares in the last quarter. Finally, State Street Corp boosted its stake in Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DNTH shares. HC Wainwright increased their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush upped their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Truist Financial boosted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $113.70 on Thursday. The company has a market cap of $6.22 billion, a price-to-earnings ratio of -27.40 and a beta of 1.22. The firm has a 50-day moving average of $99.51 and a 200-day moving average of $84.41. Dianthus Therapeutics, Inc. has a one year low of $22.06 and a one year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is owned by insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.